Search Results - "LIRAS, Jennifer L"

Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction by RIPP, Sharon L, MILLS, Jessica B, FAHMI, Odette A, TREVENA, Kristen A, LIRAS, Jennifer L, MAURER, Tristan S, DE MORAIS, Sonia M

“…Cytochrome P4503A4 (CYP3A4) is the principal drug-metabolizing enzyme in human liver. Drug-drug interactions (DDIs) caused by induction of CYP3A4 can result in…”
Get full text

In Vitro-In Vivo Extrapolation of Key Transporter Activity at the Blood-Brain Barrier by Trapa, Patrick E, Troutman, Matthew D, Lau, Thomas Y, Wager, Travis T, Maurer, Tristan S, Patel, Nandini C, West, Mark A, Umland, John P, Carlo, Anthony A, Feng, Bo, Liras, Jennifer L

“…Understanding the quantitative implications of P-glycoprotein and breast cancer resistance protein efflux is a key hurdle in the design of effective, centrally…”
Get full text

Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1 by Humphrey, John M, Movsesian, Matthew, am Ende, Christopher W, Becker, Stacey L, Chappie, Thomas A, Jenkinson, Stephen, Liras, Jennifer L, Liras, Spiros, Orozco, Christine, Pandit, Jayvardhan, Vajdos, Felix F, Vandeput, Fabrice, Yang, Eddie, Menniti, Frank S

“…We disclose the discovery and X-ray cocrystal data of potent, selective quinazoline inhibitors of PDE1. Inhibitor (S)-3 readily attains free plasma…”
Get full text

Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate) by Baran, Szczepan W, Brown, Paul C, Baudy, Andreas R, Fitzpatrick, Suzanne C, Frantz, Christopher, Fullerton, Aaron, Gan, Jinping, Hardwick, Rhiannon N, Hillgren, Kathleen M, Kopec, Anna K, Liras, Jennifer L, Mendrick, Donna L, Nagao, Ryan, Proctor, William R, Ramsden, Diane, Ribeiro, Alexandre J.S, Stresser, David, Sung, Kyung E, Sura, Radhakrishna, Tetsuka, Kazuhiro, Tomlinson, Lindsay, Van Vleet, Terry, Wagoner, Matthew P, Wang, Qin, Arslan, Sevim Yildiz, Yoder, Gorm, Ekert, Jason E

“…Complex in vitro models (CIVM) offer the potential to improve pharmaceutical clinical drug attrition due to safety and/ or efficacy concerns. For this…”
Get full text

Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling by Wager, Travis T, Liras, Jennifer L, Mente, Scot, Trapa, Patrick

“…Healthy functioning of the brain is dependent on the ability of the blood-brain barrier (BBB) and other central nervous system (CNS) barriers to protect the…”
Get more information

Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting by Patel, Nandini C, Feng, Bo, Hou, Xinjun, West, Mark A, Trapa, Patrick E, Sciabola, Simone, Verhoest, Patrick, Liras, Jennifer L, Maurer, Tristan S, Wager, Travis T

“…One of the objectives within the medicinal chemistry discipline is to design tissue targeting molecules. The objective of tissue specificity can be either to…”
Get full text

Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development by Tomlinson, Lindsay, Ramsden, Diane, Leite, Sofia Batista, Beken, Sonja, Bonzo, Jessica A., Brown, Paul, Candarlioglu, Pelin L., Chan, Tom S., Chen, Eugene, Choi, Colin K., David, Rhiannon, Delrue, Nathalie, Devine, Patrick J., Ford, Kevin, Garcia, Martha Iveth, Gosset, James R., Hewitt, Philip, Homan, Kimberly, Irrechukwu, Onyi, Kopec, Anna K., Liras, Jennifer L., Mandlekar, Sandhya, Raczynski, Arek, Sadrieh, Nakissa, Sakatis, Melanie Z., Siegel, Jeffrey, Sung, Kyung, Sunyovszki, Ilona, Van Vleet, Terry R., Ekert, Jason E., Hardwick, Rhiannon N.

“…In May 2022, there is an International Regulatory and Pharmaceutical Industry (Innovation and Quality [IQ] Microphysiological Systems [MPS] Affiliate) Workshop…”
Get full text

Solid and Solution Phase Organic Syntheses of Oligomeric Thioureas by Smith, Joseph, Liras, Jennifer L, Schneider, Stephen E, Anslyn, Eric V

“…In order to study supramolecular architectures built from unnatural oligomeric and polymeric structures, one must first have an efficient synthetic strategy to…”
Get full text

The Ratio between Endocyclic and Exocyclic Cleavage of Pyranoside Acetals Is Dependent upon the Anomer, the Temperature, the Aglycon Group, and the Solvent by Liras, Jennifer L, Lynch, Vincent M, Anslyn, Eric V

“…Several cis-fused decalin pyranosides with intramolecular nucleophiles of high effective molarity were studied to determine the ratio between endocyclic and…”
Get full text

Exocyclic and Endocyclic Cleavage of Pyranosides in Both Methanol and Water Detected by a Novel Probe by Liras, Jennifer L, Anslyn, Eric V

Get full text

Potent, selective pyrimidinetrione-based inhibitors of MMP-13 by Reiter, Lawrence A., Freeman-Cook, Kevin D., Jones, Christopher S., Martinelli, Gary J., Antipas, Amy S., Berliner, Martin A., Datta, Kaushik, Downs, James T., Eskra, James D., Forman, Michael D., Greer, Elaine M., Guzman, Roberto, Hardink, Joel R., Janat, Fouad, Keene, Nandell F., Laird, Ellen R., Liras, Jennifer L., Lopresti-Morrow, Lori L., Mitchell, Peter G., Pandit, Jayvardhan, Robertson, Donald, Sperger, Diana, Vaughn-Bowser, Marcie L., Waller, Darra M., Yocum, Sue A.

“…Using SAR from two related series of pyrimidinetrione-based inhibitors, compounds with potent MMP-13 inhibition and >100-fold selectivity against other MMPs…”
Get full text

Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14 by Blagg, Julian A., Noe, Mark C., Wolf-Gouveia, Lilli A., Reiter, Lawrence A., Laird, Ellen R., Chang, Shang-Poa P., Danley, Dennis E., Downs, James T., Elliott, Nancy C., Eskra, James D., Griffiths, Richard J., Hardink, Joel R., Haugeto, Amber I., Jones, Christopher S., Liras, Jennifer L., Lopresti-Morrow, Lori L., Mitchell, Peter G., Pandit, Jayvardhan, Robinson, Ralph P., Subramanyam, Chakrapani, Vaughn-Bowser, Marcie L., Yocum, Sue A.

“…[Display omitted] Through the use of computational modeling, a series of pyrimidinetrione-based inhibitors of MMP-13 was designed based on a lead inhibitor…”
Get full text

Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13 by Freeman-Cook, Kevin D., Reiter, Lawrence A., Noe, Mark C., Antipas, Amy S., Danley, Dennis E., Datta, Kaushik, Downs, James T., Eisenbeis, Shane, Eskra, James D., Garmene, David J., Greer, Elaine M., Griffiths, Richard J., Guzman, Roberto, Hardink, Joel R., Janat, Fouad, Jones, Christopher S., Martinelli, Gary J., Mitchell, Peter G., Laird, Ellen R., Liras, Jennifer L., Lopresti-Morrow, Lori L., Pandit, Jayvardhan, Reilly, Usa D., Robertson, Donald, Vaughn-Bowser, Marcie L., Wolf-Gouviea, Lilli A., Yocum, Sue A.

“…The discovery of novel, selective spirocyclic inhibitors of MMP-13 is reported. Explorations in the pyrimidinetrione series of MMP-13 inhibitors led to the…”
Get full text

Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13 by Noe, Mark C., Natarajan, Vijayalakshmi, Snow, Sheri L., Mitchell, Peter G., Lopresti-Morrow, Lori, Reeves, Lisa M., Yocum, Sue A., Carty, Thomas J., Barberia, John A., Sweeney, Francis J., Liras, Jennifer L., Vaughn, Marcie, Hardink, Joel R., Hawkins, Joel M., Tokar, Christopher

“…A series of pipecolic hydroxamate inhibitors of MMP-13 and aggrecanase was discovered based on screening known inhibitors of TNF-α converting enzyme (TACE)…”
Get full text

Discovery of 3-OH-3-methylpipecolic hydroxamates: Potent orally active inhibitors of aggrecanase and MMP-13 by Noe, Mark C., Natarajan, Vijayalakshmi, Snow, Sheri L., Wolf-Gouveia, Lilli A., Mitchell, Peter G., Lopresti-Morrow, Lori, Reeves, Lisa M., Yocum, Sue A., Otterness, Ivan, Bliven, Marcia A., Carty, Thomas J., Barberia, John T., Sweeney, Francis J., Liras, Jennifer L., Vaughn, Marcie

“…[Display omitted] A series of 3-hydroxy-3-methylpipecolic hydroxamate inhibitors of MMP-13 and aggrecanase was designed based on the observation of increased…”
Get full text

3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase by Noe, Mark C., Snow, Sheri L., Wolf-Gouveia, Lilli A., Mitchell, Peter G., Lopresti-Morrow, Lori, Reeves, Lisa M., Yocum, Sue A., Liras, Jennifer L., Vaughn, Marcie

“…N-Hydroxy-3-hydroxy-4-arylsulfonyltetrahydropyranyl-3-carboxamides were designed as novel inhibitors of MMP-13 and aggrecanase based on known endocyclic…”
Get full text

Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate) by Baran, Szczepan W, Brown, Paul C, Baudy, Andreas R, Fitzpatrick, Suzanne C, Frantz, Christopher, Fullerton, Aaron, Gan, Jinping, Hardwick, Rhiannon N, Hillgren, Kathleen M, Kopec, Anna K, Liras, Jennifer L, Mendrick, Donna L, Nagao, Ryan, Proctor, William R, Ramsden, Diane, Ribeiro, Alexandre J S, Stresser, David, Sung, Kyung E, Sura, Radhakrishna, Tetsuka, Kazuhiro, Tomlinson, Lindsay, Van Vleet, Terry, Wagoner, Matthew P, Wang, Qin, Arslan, Sevim Yildiz, Yoder, Gorm, Ekert, Jason E

“…Complex in vitro models (CIVM) offer the potential to improve pharmaceutical clinical drug attrition due to safety and/ or efficacy concerns. For this…”
Get more information